Results 131 to 140 of about 1,146,644 (343)

Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age [PDF]

, 2018
Judith L. Kok, Jop C. Teepen, Flora E. van Leeuwen, Wim J. E. Tissing, Sebastian Neggers, Helena J. H. van der Pal, Jacqueline J. Loonen, Dorine Bresters, Birgitta Versluys, Marry M. van den Heuvel‐Eibrink, Eline van Dulmen‐den Broeder, Margriet van der Heiden‐van der Loo, Berthe M.P. Aleman, Laurien Daniëls, Cornelis J.A. Haasbeek, Bianca A.W. Hoeben, Geert O. Janssens, John H. Maduro, Foppe Oldenburger, Caroline van Rij, Robbert J.H.A. Tersteeg, Michael Hauptmann, M. van den Berg, Annette H. Bruggink, H.N. Caron, Wil V. Dolsma, Martha A. Grootenhuis, Jaap G. den Hartogh, Nynke Hollema, Marjolijn C.J. Jongmans, Monique Jaspers, Alex V. Postma, Marc J. van de Vijver, Leontien C.M. Kremer, Cécile M. Ronckers, Cécile M Ronckers   +35 more
openalex   +1 more source

Sedation efficacy of different dose of remimazolam with sufentanil for nerve block in young and elderly patients: a randomized, controlled study [PDF]

, 2022
Xue Li, Tegeleqi Bu, Yuting Li, Ke-Qi Xie, Zhenzhen Xu, Xin-Quan Liang, Dong-Liang Mu   +6 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Quantitative Risk Analysis for N-Methyl Pyrrolidone Using Physiologically Based Pharmacokinetic and Benchmark Dose Modeling [PDF]

, 2009
Torka S. Poet, Chris Kirman, M. Bader, Christoph van Thriel, Michael L. Gargas, Paul M. Hinderliter   +5 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial [PDF]

, 2016
Julien Fonsart, Sentob Saragosti, Milad Taouk, Gilles Peytavin, Lane R. Bushman, Isabelle Charreau, Allan J. Hance, Lauriane Goldwirt, Stéphane Morel, Fabrizio Mammano, Bénédicte Loze, Catherine Capitant, François Clavel, Nadia Mahjoub, Laurence Meyer, Peter L. Anderson, Constance Delaugerre, Jean‐Michel Molina   +17 more
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?

, 2023
Lien Haverals, Laurence Roosens, Kristien Wouters, Pierre Marquet, Caroline Monchaud, Annick Massart, Daniel Abramowicz, Rachel Hellemans   +7 more
openalex   +1 more source

A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariates

, 2011
HIV dynamic studies have contributed significantly to the understanding of HIV pathogenesis and antiviral treatment strategies for AIDS patients. Establishing the relationship of virologic responses with clinical factors and covariates during long-term ...
Acosta, Edward P., Holden-Wiltse, Jeanne, Huang, Yangxin, Wu, Hulin   +3 more
core   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source